NCT02092207

Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 12 Weeks, Phase II Clinical Study to Evaluate the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 147 (actual)
• Sponsor: Yungjin Pharm. Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a controlled study to determine the effectiveness and safety of KL7016 in the treatment of adult patients with dry eye syndrome (DES).

Conditions

• Dry Eye Syndrome

Interventions

Type	Name	Description
DRUG	KL7016 900mg	oral administration, 150mg 3tab, bid
DRUG	KL7016 600mg	oral administration, 150mg 3tab, bid
DRUG	Placebo	oral administration, 150mg 3tab, bid

Timeline

• Start date: 2012-10-01
• Primary completion: 2014-06-01
• Completion: 2014-07-01
• First posted: 2014-03-20
• Last updated: 2017-12-21

Locations

9 sites across 1 country: South Korea